People and Business News — 3/23
The latest people and business news from the past month, all in one place.
People News
ProofPilot announced that its CEO Chris Venezia has been accepted into the Forbes Business Council.
HeartcoR Solutions has hired Michael Jandes as director of IT systems.
M3 Wake Research appointed Lucian Cappoli to serve as Head of Early Development and Phase I Operations.
Curavit announced its newest board member, Jackie Kent.
AutoCruitment, LLC appointed Eric Setzer as Chief Financial Officer and Kathy Twiddy appointed as General Counsel & Chief Compliance Officer.
uMotif announced that life science and healthcare executive Adam Deutsch has joined its Board of Directors.
Business News
Veeva Systems announced the increasing adoption of Veeva Vault EDC—including six of the top 20 pharma.
3H Medi Solution Inc. has selected THREAD to expand decentralized research capabilities and improve access to clinical research for patients in Japan.
Emmes announced the opening of a new office in Wilmington, North Carolina.
Cognition Health’s commercial clinical research operational processes have undergone a rigorous evidence-based assessment to achieve all seven GCSA quality standards.
Recognition
Curebase announced it has been named among Y Combinator's 2023 Top Private Companies, placing among the top 6% of all companies that appeared on the list.
Pharma Targeting is celebrating its 10-year anniversary in 2023.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
